Nabriva Therapeutics PLC
Change company Symbol lookup
Select an option...
NBRV Nabriva Therapeutics PLC
HRB H & R Block Inc
GM General Motors Co
NDAQ Nasdaq Inc
DYYXF DB Commodity Double Long ETN
KIQ Kelso Technologies Inc
MMM 3M Co
CBOE Cboe Global Markets Inc
PFE Pfizer Inc
DOW Dow Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Pharmaceuticals | Small Cap Growth
Based in Ireland
Company profile

Nabriva Therapeutics plc is a biopharmaceutical company engaged in the commercialization and development of anti-infective agents to treat serious infections. The Company’s product XENLETA (lefamulin), is a semi-synthetic pleuromutilin antibiotic for systematic administration in humans. It inhibits the synthesis of bacterial protein, which is required for bacteria to grow by binding with high affinity, high specificity and at molecular targets that are different than other antibiotic classes. The Company is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.

Price
Delayed
$0.626
Day's Change
-0.0356 (-5.38%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.6599
Day's Low
0.6001
Volume
(Heavy Day)

Today's volume of 1,979,003 shares is on pace to be much greater than NBRV's 10-day average volume of 2,903,555 shares.

1,979,003

FedEx's stock gains after BofA Securities says buy, boosts price target by 20%

11:27 am ET April 13, 2020 (MarketWatch)
Print

Shares of FedEx Corp. (FDX) gained 0.4% in morning trading, to buck the steep slide in the broader stock market, after BofA Securities analyst Ken Hoexter turned bullish on the package delivery giant, citing the positives associated with Amazon.com Inc.'s (AMZN) decision last week to pause its competing third-party delivery business (http://www.marketwatch.com/story/fedex-ups-stocks-surge-as-investors-cheer-news-of-amazon-pausing-test-of-competing-service-2020-04-08). Hoexter raised his rating to buy from neutral, and boosted his stock price target by 20%, to $140 from $117. He said Amazon's pausing its Amazon Shipping business "highlights the difficulty" to efficiently enter the business. "We also highlight the integration of FedEx's Express and Ground networks (http://www.marketwatch.com/story/fedexs-stock-swings-to-sharp-gains-after-express-pairs-with-ground-for-residential-deliveries-2020-02-07) for select e-commerce deliveries, which should reduce network costs, its deployment of dynamic routing software at Ground, the conversion of SmartPost packages into Ground, and the shutdown of belly space, which is aiding airfreight rates," Hoexter wrote in a note to clients. He noted, however, that only about 20% of FedEx revenue comes from business-to-consumer deliveries, while the impacts from the COVID-19 pandemic on its business-to-business business are "significant." FedEx's stock has lost 22.9% over the past three months, while the Dow Jones Transportation Average has dropped 27.2% and the Dow Jones Industrial Average has declined 19.6%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

April 13, 2020 11:27 ET (15:27 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.